Europe Cardiac Rhythm Management Devices Market Industry: Market Size & Forecast 2026

Europe's CRM devices market covers implantable systems designed to manage abnormal heart rhythms, including bradycardia, tachycardia, and heart failure. The segment encompasses three primary product categories: cardiac pacemakers, implantable cardioverter defibrillators (ICDs), and cardiac resynchronization therapy (CRT) devices, each serving distinct clinical needs. Elective implantation procedures, primarily conducted in hospital cardiac units and specialized clinics, account for the majority of market activity.

• •Market valued at approximately $27.8 billion in 2025 with a compound annual growth rate of 5.0%
• •Three core device categories: pacemakers, ICDs, and CRT devices
• •Primary end users include hospitals, specialty cardiology clinics, and ambulatory surgery centers

The aging European population is the primary catalyst, as atrial fibrillation, bradycardia, and heart failure incidence rise significantly with age. Approximately 20% of Europeans are aged 65 or older, and this demographic segment experiences cardiac arrhythmias at disproportionately high rates. Additionally, clinical evidence demonstrating reduced mortality through device therapy continues to expand treatable patient populations, while favorable reimbursement policies across major European health systems support broader device adoption.

• •Rising prevalence of cardiovascular disease among Europe's aging population
• •Clinical guidelines expanding indications for CRM device implantation
• •Technological advancements improving device longevity, safety, and patient outcomes

By product type, defibrillators represent the largest revenue segment, followed by pacemakers and CRT devices, though leadless pacemaker adoption is accelerating. Germany leads the European market by volume, benefiting from a large patient population and advanced cardiology infrastructure, followed by France, the United Kingdom, Italy, and Spain. Eastern European markets are expanding more rapidly as healthcare systems modernize and device access improves.

• •Defibrillators, pacemakers, and CRT devices constitute the primary product segments
• •Germany, France, the United Kingdom, Italy, and Spain dominate market share
• •Eastern European markets exhibit faster growth rates as healthcare infrastructure develops

What are the recent trends and outlook?

Leadless pacemaker technology is gaining clinical acceptance, offering reduced complication rates compared to traditional transvenous systems, while subcutaneous ICD technology addresses specific patient populations. Remote monitoring capabilities embedded in modern devices enable outpatient follow-up, reducing healthcare system burden and improving patient adherence. The market is expected to sustain its 5.0% growth trajectory through 2030, with continued innovation in battery longevity, MRI-compatibility, and integration with digital health platforms driving adoption.

• •Leadless pacing and subcutaneous ICDs represent next-generation product innovations
• •Remote monitoring and digital health integration are becoming standard features
• •Continued investment in research and development across major manufacturers supports sustained market growth